Consensus Praxis Precision Medicines, Inc.

Equities

PRAX

US74006W2070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
50.78 ^USD	-3.11%		+0.42%	+127.92%

Apr. 11	Certain Common Stock of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024.	CI
Apr. 11	Certain Restricted Stock Units of Praxis Precision Medicines, Inc. are subject to a Lock-Up Agreement Ending on 11-APR-2024.	CI

Evolution of the average Target Price on Praxis Precision Medicines, Inc.

Price target over the last 5 years

History of analyst recommendation changes

3ac901bed8470f65c.sPHf3McL0VZNfSJu9PU6TrQRxh4Pebtb-mdtztQe0kA.hba3t41xmTMsFhFcnoV9BO58iWdADM8cywAhj_kolwHkwOaGj0WoHSoiUQ~1483edd54f7c07fce6e69f6fe0fc4f33

Analyst Recommendations on Praxis Precision Medicines, Inc.

Wedbush Trims Price Target on Praxis Precision Medicines to $40 From $41 After $200 Million Secondary Offering, Maintains Neutral Rating	Apr. 08	MT
Jefferies Adjusts Praxis Precision Medicines' Price Target to $128 From $75, Keeps Buy Rating	Mar. 26	MT
Wedbush Adjusts Praxis Precision Medicines' Price Target to $41 From $29, Maintains Neutral Rating	Mar. 05	MT
North American Morning Briefing : Rate Doubts Keep -2-	Feb. 06	DJ
Wedbush Adjusts Praxis Precision Medicines' Price Target to $16 From $15 After Reverse Stock Split, Keeps Neutral Rating	Nov. 30	MT
Wedbush Trims Praxis Precision Medicines' PT to $1 From $2 After 'Relatively Uneventful' Q3 Results; Keeps Neutral Rating	Nov. 07	MT
Truist Initiates Praxis Precision Medicines at Buy With $10 Price Target	23-09-19	MT
HC Wainwright Adjusts Price Target on Praxis Precision Medicines to $7 From $15, Keeps Buy Rating	23-08-10	MT
Jefferies Starts Praxis Precision Medicines at Buy With $4 Price Target	23-06-02	MT
William Blair Downgrades Praxis Precision Medicines to Market Perform Rating From Outperform	23-03-06	MT
Wedbush Adjusts Praxis Precision Medicines Price Target to $2 From $3, Maintains Neutral Rating	23-03-03	MT
HC Wainwright Reiterates Praxis Precision Medicines at Buy With $16 Price Target	23-02-03	MT
Wedbush Trims Praxis Precision Medicines' Price Target to $3 From $4 After Increased Financing Assumptions, Keeps Neutral Rating	22-11-10	MT
Piper Sandler Adjusts Price Target on Praxis Precision Medicines to $18 From $65, Reiterates Overweight Rating	22-06-08	MT
HC Wainwright Adjusts Price Target on Praxis Precision Medicines to $10 From $48, Reiterates Buy Rating	22-06-07	MT
BofA Securities Cuts Praxis Precision Medicines to Neutral From Buy, Price Target to $4 From $26	22-06-07	MT
Wedbush Downgrades Praxis Precision Medicines to Neutral From Outperform, Adjusts Price Target to $4 From $34	22-06-06	MT
Wedbush Adjusts Price Target on Praxis Precision Medicines to $34 From $40, Keeps Outperform Rating	22-05-10	MT
Wedbush Trims Price Target on Praxis Precision Medicines to $40 From $42, Keeps Outperform Rating	22-04-28	MT
Wedbush Adjusts Price Target on Praxis Precision Medicines to $42 From $45, Citing PRAX-562 Launch Estimate; Outperform Rating Kept	22-02-28	MT
HC Wainwright Starts Praxis Precision Medicines at Buy With $48 Price Target	21-12-16	MT
Wedbush Adjusts Price Target on Praxis Precision Medicines to $45 From $50; Outperform Rating Kept	21-11-04	MT
PRAXIS PRECISION MEDICINES : BofA Securities Starts Praxis Precision Medicines at Buy With $28 Price Target	21-08-26	MT
PRAXIS PRECISION MEDICINES : Wedbush Adjusts Praxis Precision Medicines PT to $50 From $55, Maintains Outperform Rating	21-08-16	MT
PRAXIS PRECISION MEDICINES : Wedbush Further Adjusts Praxis Precision Medicines' Price Target to $55 From $60, Citing Follow-On Offering; Outperform Rating Kept	21-05-17	MT